KALA BIO (KALA) Projected to Post Earnings on Friday

KALA BIO (NASDAQ:KALA) is expected to issue its quarterly earnings data before the market opens on Friday, April 4th. Analysts expect the company to announce earnings of ($2.28) per share for the quarter.

KALA BIO (NASDAQ:KALA) last posted its quarterly earnings data on Monday, March 31st. The company reported ($1.74) earnings per share for the quarter, topping the consensus estimate of ($2.28) by $0.54. On average, analysts expect KALA BIO to post $-11 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

KALA BIO Stock Performance

NASDAQ:KALA opened at $5.73 on Wednesday. The stock has a market capitalization of $34.90 million, a P/E ratio of -0.46 and a beta of -2.19. KALA BIO has a 1 year low of $4.21 and a 1 year high of $11.20. The firm has a 50 day moving average of $7.63 and a 200-day moving average of $6.81. The company has a current ratio of 2.15, a quick ratio of 2.15 and a debt-to-equity ratio of 3.18.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of KALA BIO in a research report on Thursday, February 13th.

Insiders Place Their Bets

In other KALA BIO news, CEO Mark T. Iwicki sold 5,779 shares of the business’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $7.63, for a total value of $44,093.77. Following the completion of the transaction, the chief executive officer now directly owns 280,076 shares of the company’s stock, valued at approximately $2,136,979.88. The trade was a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 9,506 shares of company stock valued at $72,531 in the last 90 days. 8.32% of the stock is currently owned by insiders.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.